Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
teriparatide + romosozumab
- Development stage
- Phase 4
- Lead developer
- Massachusetts General Hospital
- Modality
- Peptides, Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
teriparatide + romosozumab is a combination therapy consisting of two bone-forming (anabolic) agents used for the treatment of severe osteoporosis. Teriparatide is a recombinant human parathyroid hormone (PTH 1-34) analog that stimulates bone formation by activating the parathyroid hormone 1 receptor (PTH1R). Romosozumab is a humanized monoclonal antibody that targets and inhibits sclerostin, a negative regulator of bone formation, thereby promoting bone building while simultaneously reducing bone resorption. The co-administration of these two agents is being investigated to evaluate whether combining their distinct anabolic pathways can produce synergistic increases in bone mineral density (BMD) and more effectively reduce fracture risk in postmenopausal women with severe osteoporosis.
- Other names
- Combined Anabolic TherapyEvenity + ForteoForteo + Evenityromosozumab + teriparatideromosozumab and teriparatideteriparatide and romosozumab
02
Targets
PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)SOST (Sclerostin)
Beyond the preview
Go deeper on teriparatide + romosozumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on teriparatide + romosozumab.